このエントリーをはてなブックマークに追加
ID 52936
Sort Key
9
Title Alternative
Molecular target therapies in rheumatic diseases
FullText URL
Thumnail 126_227.pdf 332 KB
Author
Keywords
リウマチ性疾患
自己免疫疾患
生物学的製剤
分子標的薬
Note
特集 (Feature Articles)
Publication Title
岡山医学会雑誌
Published Date
2014-12-01
Volume
volume126
Issue
issue3
Publisher
岡山医学会
Publisher Alternative
Okayama Medical Association
Start Page
227
End Page
230
ISSN
0030-1558
NCID
AN00032489
Content Type
Journal Article
OAI-PMH Set
岡山大学
language
日本語
Copyright Holders
Copyright (c) 2014 岡山医学会
File Version
publisher
Refereed
True
DOI
NAID
Eprints Journal Name
joma
References
1) Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, Koike T : Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis (2011) 70, 1208-1215.
2) Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Kupper H, Arora V, Tanaka Y : Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis : the HOPEFUL 1 study. Ann Rheum Dis (2014) 73, 536-543.
3) Palframan R, Airey M, Moore A, Vugler A, Nesbitt A : Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods (2009) 348, 36-41.
4) Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Ghogomu ET, Tugwell P : A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis : a Cochrane overview. CMAJ (2009) 181, 787-796.
5) Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, Schett G, Amital H, Navarro-Sarabia F, Hou A, Bernasconi C, Huizinga TW : Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders : 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis (2013) 72, 43-50.
6) Axmann R, Herman S, Zaiss M, Franz S, Polzer K, Zwerina J, Herrmann M, Smolen J, Schett G : CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis (2008) 67, 1603-1609.
7) Ottaviani S, Moltó A, Ea HK, Neveu S, Gill G, Brunier L, Palazzo E, Meyer O, Richette P, Bardin T, Allanore Y, Lioté F, et al. : Efficacy of anakinra in gouty arthritis : a retrospective study of 40 cases. Arthritis Res Ther (2013) 15, R123.
8) Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, et al. : Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med (2010) 363, 221-232.
9) Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, et al. : EULAR recommenda-tions for the management of primary small and medium vessel vasculitis. Ann Rheum Dis (2009) 68, 310-317.